[{"id":"2f08fbe6-a3bd-4df8-b1a3-43fb32cfa623","acronym":"CTMX-2009-002","url":"https://clinicaltrials.gov/study/NCT04596150","created_at":"2021-01-19T20:30:03.686Z","updated_at":"2024-07-02T16:35:22.560Z","phase":"Phase 2","brief_title":"Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer","source_id_and_acronym":"NCT04596150 - CTMX-2009-002","lead_sponsor":"CytomX Therapeutics","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)"],"overall_status":"Completed","enrollment":" Enrollment 125","initiation":"Initiation: 12/29/2020","start_date":" 12/29/2020","primary_txt":" Primary completion: 06/02/2023","primary_completion_date":" 06/02/2023","study_txt":" Completion: 06/02/2023","study_completion_date":" 06/02/2023","last_update_posted":"2024-01-23"}]